Omaveloxolone Shows Range of Neurologic Benefits to FA Patients in MOXIe Trial
After nearly one year of its use, omaveloxolone (RTA 408) significantly improved neurological function across several clinical measures in people with Friedreich’s ataxia (FA), and was generally safe and well tolerated, according to results from the MOXIe Phase 2 trial. These findings were published…